Levomilnacipran is indicated for the treatment of:
a. Hypertension
b. Depression
c. Epilepsy
d. Renal carcinoma
e. Arrhythmia
Answer:(b). Levomilnacipran (Fetzima), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD).
The recommended dose range for Levomilnacipran (Fetzima) is 40 mg to 120 mg once daily, with or without food. Levomilnacipran (Fetzima) should be initiated at 20 mg once daily for 2 days and then increased to 40 mg once daily. Based on efficacy and tolerability, Levomilnacipran (Fetzima) may then be increased in increments of 40 mg at intervals of 2 or more days. The maximum recommended dose is 120 mg once daily.
At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Levomilnacipran (Fetzima). Conversely, at least 7 days should be allowed after stopping Levomilnacipran (Fetzima) before starting an MAOI antidepressant.
Suicidal thoughts and behaviors in adolescents and young adults, serotonin syndromes, elevated blood pressure, activation of mania/hypomania, seizure and hyponatremia are reported side effects of Levomilnacipran.
www.pharmacyexam.com Try our Naplex Questions QBank.
Ready for the full prep?
Continue your preparation with full NAPLEX practice questions, question bank access, and study materials.
Go to NAPLEX Study Materials